Michael Dougherty - Atea Pharmaceuticals Independent Director

AVIR -  USA Stock  

USD 26.23  0.90  3.32%

  Director
Mr. Michael R. Dougherty is Independent Director of the Company. He was Executive Chairman of Celator Pharmaceuticals, Inc., a publiclytraded biotechnology company from August 2015 to July 2016. Mr. Dougherty was a director at Celator Pharmaceuticals, Inc. from July 2013 to July 2016 and was Chairman of the Board of Directors from September 2014 to August 2015. Mr. Dougherty was Chief Executive Officer and a member of the Board of Directors of Kalidex Pharmaceuticals, Inc. from May 2012 to October 2012. Mr. Dougherty was the President and Chief Executive Officer and a director of Adolor Corporationrationration, a publiclytraded biotechnology company, from December 2006 until December 2011. Mr. Dougherty joined Adolor as Senior Vice President of Commercial Operations in November 2002. From November 2000 to November 2002, Mr. Dougherty was President and Chief Operating Officer of Genomics Collaborative, Inc., a privatelyheld functional genomics company. Previously, Mr. Dougherty served in a variety of senior positions at Genaera Corporationrationration, a publiclytraded biotechnology company, including as President and Chief Executive Officer and at Centocor, Inc., a publiclytraded biotechnology company, including as Senior Vice President and Chief Financial Officer. Mr. Dougherty currently serves as a director of Cempra, Inc., and Trevena, Inc., which are publiclytraded companies. Mr. Dougherty was a director of Viropharma Incorporated, a publiclytraded biotechnology company, from 2004 to January 2014. Mr. Dougherty received a B.S. from Villanova University. Mr. Doughertys broad understanding of key issues in the biotechnology industry, including finance, research and development, sales and marketing, strategy, and operations and his significant executive experience as a chief executive officer andor director at several biotechnology companies led to the conclusion that he should serve on the Companys Board of Directors.
Age: 58  Director Since 2013      
678 221-3343  www.aviragentherapeutics.com
Dougherty received a B.S. from Villanova University.

Michael Dougherty Latest Insider Activity

Tracking and analyzing the buying and selling activities of Michael Dougherty against Atea Pharmaceuticals stock is an integral part of due diligence when investing in Atea Pharmaceuticals. Michael Dougherty insider activity provides valuable insight into whether Atea Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Atea Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Atea Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Atea Pharmaceuticals Management Efficiency

Atea Pharmaceuticals has return on total asset (ROA) of 1.7 % which means that it generated profit of $1.7 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (3.86) %, meaning that it created substantial loss on money invested by shareholders. Atea Pharmaceuticals management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. As of 09/18/2021, Return on Invested Capital is likely to grow to 0.07, while Return on Investment is likely to drop (20.28) . Atea Pharmaceuticals Total Assets are relatively stable at the moment as compared to the past year. Atea Pharmaceuticals reported last year Total Assets of 863.63 Million. As of 09/18/2021, Current Assets is likely to grow to about 931.6 M, while Net Current Assets as percentage of Total Assets are likely to drop 102.91.
The market value of Atea Pharmaceuticals is measured differently than its book value, which is the value of Atea Pharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Atea Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Atea Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atea Pharmaceuticals' market value can be influenced by many factors that don't directly affect Atea Pharmaceuticals underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atea Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Atea Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atea Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Similar Executives

Showing few of many executives

DIRECTOR Since

Jerry XiaoDiamedica Therapeutics
2016
Anthony TjanEquillium
2005
Marc KozinDicerna Pharmaceutic
2019
Charles McDermottEquillium
2018
Shalini SharpPrecision Biosciences
2018
Stanley PlotkinDynavax Technologies
2005
Douglas ColeEditas Medicine
2013
Jack KayeDyadic International
2015
Marc LavineEquillium
2006
Jennifer CookDenali Therapeutics
2018
Barry BucklandDyadic International
2018
Harry AlcornDiamedica Therapeutics
2018
Brian HalakDicerna Pharmaceutic
2010
Stephen HoffmanDicerna Pharmaceutic
2007
Douglas ColeDenali Therapeutics
2015
Kevin BuchiDicerna Pharmaceutic
2019
Frank GerardiDyadic International
2008
Andrew HirschEditas Medicine
2017
Akshay VaishnawEditas Medicine
2016
Peter KolchinskyDicerna Pharmaceutic
2013
Michael TarnokDyadic International
2015
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts. Atea Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs people. Atea Pharmaceuticals (AVIR) is traded on NASDAQ Exchange in USA. It is located in 2500 Northwinds Parkway Suite 100, Alpharetta, GA 30009, United States and employs 39 people. Atea Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Atea Pharmaceuticals Leadership Team

Elected by the shareholders, the Atea Pharmaceuticals' board of directors comprises two types of representatives: Atea Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Atea Pharmaceuticals. The board's role is to monitor Atea Pharmaceuticals' management team and ensure that shareholders' interests are well served. Atea Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Atea Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
John Richard, Independent Director
Anne VanLent, Independent Director
Mark Colonnese, CFO, Executive Vice President
Russell Plumb, Executive Chairman of the Board
Michael Dunne, Independent Director
Joseph Patti, President CEO, Director
Armando Anido, Independent Director
Geoffrey Cox, Independent Director
Michael Dougherty, Independent Director

Atea Pharmaceuticals Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Atea Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Atea Pharmaceuticals Investors Sentiment

The influence of Atea Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Atea Pharmaceuticals. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Current Sentiment - AVIR

Atea Pharmaceuticals Investor Sentiment

Macroaxis portfolio users are unresponsive in their sentiment towards investing in Atea Pharmaceuticals. What is your sentiment towards investing in Atea Pharmaceuticals? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Pair Trading with Atea Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atea Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atea Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Atea Pharmaceuticals Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Atea Pharmaceuticals and Equillium. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Please continue to Trending Equities. Note that the Atea Pharmaceuticals information on this page should be used as a complementary analysis to other Atea Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Complementary Tools for Atea Pharmaceuticals Stock analysis

When running Atea Pharmaceuticals price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
The market value of Atea Pharmaceuticals is measured differently than its book value, which is the value of Atea Pharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Atea Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Atea Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atea Pharmaceuticals' market value can be influenced by many factors that don't directly affect Atea Pharmaceuticals underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atea Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Atea Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atea Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.